Cytosorbents Corporation (CTSO) Stock Analysis & Winston Score

Cytosorbents is a medical device company that makes a blood-filtering technology called CytoSorb. The device is designed to remove dangerous levels of toxins, drugs, and inflammatory substances from a patient's blood during serious medical crises like sepsis, organ failure, or heart surgery. Hospitals and intensive care units in Europe and other countries are the main customers. The company earns revenue primarily by selling disposable CytoSorb cartridges, which are single-use filters that hospitals buy each time the treatment is needed. Cytosorbents operates mainly in Europe, where CytoSorb has broad regulatory approval, while its US approval remains limited to specific uses like cardiac surgery. The company has not yet reached profitability, as reflected in its negative operating margin, and its biggest challenge is expanding US regulatory approvals and convincing more hospitals to adopt the technology at a scale large enough to cover its ongoing research and operating costs.